Overview

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer. Our lead therapy is AO-176, an anti-CD47 antibody which is optimized for anti-cancer activity. We are advancing AO-176 in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with hematologic malignancies, both as monotherapy and in combination with standard therapies. Our company is headquartered in Brisbane, CA and we have a research team based in St. Louis, MO. Our team is committed to our mission to develop new therapies for patients living with cancer.

Leadership Team

Laurence Blumberg, M.D.

President and CEO

Louie Naumovski, M.D., Ph.D.

Chief Medical Officer

Daniel Pereira, Ph.D.

Chief Scientific Officer

Amit Agarwal M.D., Ph.D.

Senior Vice President, Clinical Development

Steve DeMattos

Senior Vice President, Clinical Operations

Arun Kashyap, Ph.D.

Vice President, Research

David Boisvert, Ph.D.

Vice President, Chemistry, Manufacturing, & Controls (CMC)

Carrie Baker Brachmann, Ph.D.

Vice President, Translational Medicine

Kirsten Anderson

Vice President, Finance

Board of Directors

Scientific Advisory Board

Investors

Eventide
Cowen
3x5 Partners
Avego
Rivervest
Roche
Lightchain
Adage
FMB
Avego
Broadfin

Contact Us

Reach us at
Headquarters
2000 Sierra Point Parkway, Suite 700 Brisbane, CA 94005
Scientific Research Laboratory
4340 Duncan Avenue, Suite 301 St. Louis, MO 63110